Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Zacks Investment Research9/24/2026Positive
VRTX
Vertex Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$133.37B
P/E Ratio
30.24
EPS
$17.40
Beta
0.32
52W High
$560.25
52W Low
$384.39
50-Day MA
$513.50
200-Day MA
$471.43
Dividend Yield
—
Profit Margin
35.00%
Forward P/E
24.10
PEG Ratio
1.90
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $12.59B |
| Gross Profit (TTM) | $6.92B |
| EBITDA | $5.10B |
| Operating Margin | 38.10% |
| Return on Equity | 23.50% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $49.51 |
| Book Value | $79.92 |
| Price-to-Book | 6.46 |
| Price-to-Sales (TTM) | 10.59 |
| EV/Revenue | 9.93 |
| EV/EBITDA | 24.51 |
| Quarterly Earnings Growth (YoY) | 8.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $253.46M |
| Float | $252.69M |
| % Insiders | 0.21% |
| % Institutions | 97.97% |
Historical Volatility
HV 10-Day
13.81%
HV 20-Day
19.83%
HV 30-Day
25.09%
HV 60-Day
29.41%
HV Rank
36.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($570.32 target)
4
Strong Buy19
Buy4
Hold1
Sell1
Strong SellLatest News
Vertex Posts Positive Phase II Data on Kidney Disease Drug
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Zacks Investment Research9/23/2026Positive
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research9/22/2026Positive
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to.
Business Wire9/22/2026Neutral
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
MarketBeat9/14/2026Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha9/10/2026Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha9/10/2026Neutral
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research9/8/2026Positive
Rep. David Taylor discloses 6 new Congressional stock trades
Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, and a regional bank.
Finbold9/7/2026Negative
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha Pai will also participate in a fireside chat at the 2026 Cantor G.
Business Wire8/26/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRTX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026